Core Viewpoint - The company Baipusais (301080.SZ) has disclosed its performance forecast for the year 2025, indicating a significant increase in net profit attributed to shareholders [1] Financial Performance - The company expects a net profit attributable to shareholders ranging from 160 million to 190 million yuan, representing a year-on-year growth of 29.21% to 53.43% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 155 million and 185 million yuan, with a year-on-year increase of 30.13% to 55.31% [1]

证券代码：301080 证券简称：百普赛斯 公告编号：2026-004 北京百普赛斯生物科技股份有限公司 关于与专业投资机构共同投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 北京百普赛斯生物科技股份有限公司（以下简称"公司"）全资子公司 ACROBIOSYSTEMS HONGKONG LIMITED 之全资子公司 ACROBiosystems Corp.以自 有资金出资不超过 100 万美元认购专业投资机构 BroadOak Asset Management, LLC 正在募集的基金的份额（0.9%），成为其有限合伙人。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》等相关法律法规以及《公司章 程》的规定，本次投资属于管理层审批权限内，无需提交董事会审议。 主要投资领域：生命科学工具及医药服务领域企业，重点关注生命科学工具、 诊断服务、研究及生物医药外包服务等细分领域 关联关系或其他利益关系说明：BroadOak Asset Management, LLC与公司不 ...

Financial Projections - The company expects a net profit attributable to shareholders of between ¥160 million and ¥190 million for 2025, representing a year-on-year growth of 29.21% to 53.43%[4] - The net profit after deducting non-recurring gains and losses is projected to be between ¥155 million and ¥185 million, reflecting a year-on-year increase of 30.13% to 55.31%[4] - The company anticipates a revenue of ¥837 million for 2025, which indicates a year-on-year growth of approximately 30%[6] - The specific data for the 2025 performance will be detailed in the annual report, and investors are advised to make cautious decisions[10] Product and Service Development - The product matrix includes over 5,000 SKUs, focusing on a comprehensive ecosystem of "products + services + platforms" to meet the full lifecycle needs of global clients[7] - The company is focusing on innovative therapy research, particularly in areas such as in vivo CAR-T/CAR-NK, XDC/ADC, and cell and gene therapy[8] - The company has developed several key products, including AI-engineered recombinant proteins and GMP-grade growth factors for stem cell drug development[8] Supply Chain and Quality Management - The company has established a global supply chain network covering nearly 80 countries and regions, serving over 11,000 end customers, including major pharmaceutical companies[7] - Cost control and quality stability have been enhanced through optimized protein expression efficiency and improved global supply chain management[9] - The company adheres to international quality standards such as ISO9001:2015 and cGMP to enhance operational efficiency and global delivery capabilities[9]

Market Overview - The market experienced fluctuations throughout the day, with the Shanghai Composite Index rising by 0.27%, the Shenzhen Component Index increasing by 0.09%, and the ChiNext Index declining by 0.57% [1] - A total of 1,739 stocks rose, with 84 hitting the daily limit up, while 3,640 stocks fell [2] Stock Performance - Among the rising stocks, 169 had gains exceeding 7%, 105 gained between 5-7%, and 252 rose between 3-5% [3] - Conversely, 2,912 stocks saw declines of 0-3%, 558 fell by 3-5%, and 58 dropped by more than 7% [3] - Resource stocks surged, particularly gold stocks, with Sichuan Gold achieving four consecutive limit-ups, and both Zhaojin Mining and Hunan Gold achieving three consecutive limit-ups [3] Sector Highlights - Oil and gas stocks collectively rose, with Tongyuan Petroleum and Zhongman Petroleum hitting the daily limit up, and China National Offshore Oil Corporation (CNOOC) increasing over 6% to reach a new high [4] - The non-ferrous metals sector strengthened, with silver stocks achieving seven consecutive limit-ups, and China Aluminum hitting the daily limit up, marking a 16-year high [5] - The coal sector also saw gains, with Shanxi Coking Coal and Shaanxi Black Cat both hitting the daily limit up [7] Declines - The pharmaceutical and medical stocks faced adjustments, with Bibet and Baipusai dropping over 10% [8] Trading Volume and Activity - The total trading volume reached approximately 29,922.93 billion, with a notable increase in trading activity for major ETFs, including the CSI 300 ETF from Huatai-PB, which exceeded 30 billion in trading volume [11]

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 【导读】震荡上涨 中国基金报记者 泰勒 兄弟姐妹们啊，回顾一下今天市场发生了什么事情吧。 1月28日，市场全天震荡，截至收盘，沪指涨0.27%，深成指涨0.09%，创业板指跌0.57%。 两市共1739只个股上涨，84只个股涨停，3640只个股下跌。 | 880005 张跌家数 | | | | | --- | --- | --- | --- | | 日中 | 涨停 | | 84 | | 涨幅 | > 7% | | 169 | | 涨幅 | 5-7% | 1 | 105 | | 涨幅 | 3-5% | | 252 | | 张唱 | 0-3% | | 1213 | | 跌幅 | 0-3% | | 2912 | | 跌幅 | 3-5% | | 258 | | 跌幅 | 5-7% | | 112 | | 跌幅 | > 7% | | 58 | | 其中 跌停 | | | 28 | | 上涨家数 | | | 1739 | | 下跌家药 | | | 3640 | | 平盘停牌 当日种数 | | | ae | | | | | 5475 | | 总成交额 ...

Market Overview - The three major indices showed mixed performance, with the Shanghai Composite Index rising by 0.49% to 4160.01, the Shenzhen Component Index increasing by 0.09% to 14342.74, and the ChiNext Index declining by 0.37% to 3330.39 [1][2]. Sector Performance - Precious metals, industrial metals, and petrochemicals sectors performed strongly, while solar energy, pharmaceuticals, and aerospace sectors experienced fluctuations [2]. - The basic metals sector saw significant gains, with copper and aluminum industries leading the rise, as multiple stocks hit the daily limit up [6]. Stock Highlights - Notable stocks included China National Offshore Oil Corporation, China Petroleum, and China Unicom, which showed strong performance [4]. - The aluminum futures market saw a rise of over 4%, with the main contract reported at 25345 yuan/ton [8]. Biotechnology Sector - The biotechnology sector faced declines, with several companies such as Zhijiang Biology and Baipusais losing over 9% [10][11]. Solar Energy Sector - The solar energy sector faced downward adjustments, with companies like High Measurement and Maiwei experiencing drops exceeding 6% [11].

重组蛋白板块领跌，下跌1.42%，其中百普赛斯下跌7.3%，近岸蛋白下跌2.81%，海特生物下跌2.16%， 三生国健跌超3%。（AI生成） ...

百普赛斯公告，公司已于2026年1月26日向香港联合交易所有限公司递交了发行境外上市股份(H股)并在 香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 ...

鉴于本次发行上市的认购对象将仅限于符合相关条件的境外投资者及依据 中国相关法律法规有权进行境外证券投资的境内合格投资者，公司将不会在境内 证券交易所的网站和符合境内监管机构规定条件的媒体上刊登该申请资料，但为 使境内投资者及时了解该等申请资料披露的本次发行上市以及公司的其他相关 信息，现提供该申请资料在香港联交所网站的查询链接供查阅： 证券代码：301080 证券简称：百普赛斯 公告编号：2026-002 北京百普赛斯生物科技股份有限公司 关于向香港联交所递交境外上市股份(H 股)发行上市申请 并刊发申请资料的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）已于 2026 年 1 月 26 日向香港联合交易所有限公司（以下简称"香港联交所"）递交了发行境 外上市股份（H 股）并在香港联交所主板挂牌上市（以下简称"本次发行上市"） 的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 该申请材料为公司按照香港证券及期货事务监察委员会（以下简称"香港证 监会"）及香港联交所的要求编制和刊发，为草拟 ...